Direct-to-Patient Trials: Supply Chain Considerations for Decentralized and Hybrid Studies

For decades the clinical supply chain had a comfortable stopping point: the site. Drug moved from manufacturing, through depots, to the investigator site, and the site handled the last, most sensitive step — dispensing to the patient. Decentralized and direct-to-patient trials erase that stopping point. Now the supply chain runs all the way to the patient's front door.

That shift is good for patients — it reduces the burden of travel and can widen access and improve retention. But it fundamentally changes the supply chain's shape, its risks, and its responsibilities. The last mile is no longer a controlled clinical environment; it's someone's home. Here's what that actually requires.

What "direct-to-patient" and "decentralized" mean

Decentralized clinical trials (DCTs) move some or all trial activities out of the traditional site and closer to the patient — through home visits, telemedicine, local providers, and direct shipment of supplies.

Direct-to-patient (DtP) supply is the logistics piece of that: delivering investigational product directly to the patient's home rather than to a site. A related model, direct-from-patient, handles samples or returns coming back the other way.

Most real-world studies are hybrid — some patients and visits remain site-based while others are handled remotely — which means the supply chain often has to support both models at once.

How the supply chain changes

The last mile is now uncontrolled

At a site, storage conditions, handling, and dispensing happen in a qualified environment by trained staff. Deliver to a home and none of that is guaranteed. There may be no one in when the courier arrives, no appropriate storage, and no trained professional to receive a temperature-sensitive product. The most sensitive step now happens in the least controlled setting.

Cold chain has to reach the doorstep

Temperature-controlled product now has to maintain its cold chain all the way to a residential address — and account for what happens if the patient isn't home, if the package sits on a porch, or if home storage is inadequate. The cold chain doesn't end at a depot or a site fridge anymore; it ends in someone's kitchen.

Chain of custody extends to the patient

Tracking and accountability have to follow the product to the individual and, where relevant, back again. Confirming the right patient received the right product in usable condition — and reconciling what was used, returned, or destroyed — is harder outside a site's controlled process.

Blinding has to survive delivery

In a blinded trial, the product arriving at a patient's home must not reveal treatment assignment through packaging, labeling, or delivery paperwork. Preserving the blind is more complex when the patient handles the package directly.

Patient privacy enters the supply chain

Shipping to homes means handling patients' names and addresses — personal data that the supply chain hasn't traditionally held. That introduces privacy and data-protection obligations, and often a need to keep patient identity separated from trial information.

Regulations vary and are still evolving

Whether and how DtP shipment is permitted varies by country and continues to develop. Some jurisdictions restrict direct shipment of investigational product or impose specific conditions, so the model has to be validated market by market.

Considerations for making DtP work

If you're designing a direct-to-patient or decentralized model, these are the considerations that most determine success:

• Design the last mile deliberately. Plan for failed deliveries, home storage limitations, and the absence of trained staff — with defined fallbacks (redelivery, alternative receipt, or a home healthcare professional for sensitive products).
• Extend cold chain validation to the home. Use packaging validated for realistic worst-case last-mile scenarios, with monitoring that follows the shipment to the door.
• Build patient-level chain of custody and reconciliation. Confirm delivery to the right patient, track condition on arrival, and manage returns and destruction with the same rigor a site would.
• Protect the blind through the last mile. Ensure packaging, labeling, and paperwork reveal nothing, even when handled by the patient.
• Handle personal data carefully. Separate patient identity from trial data where possible, and use logistics partners who can manage privacy obligations.
• Choose specialist partners. DtP is a specialist capability. Couriers and home-healthcare providers experienced in clinical DtP — not general parcel delivery — are essential for temperature-sensitive or blinded products.
• Map the regulatory position per country. Confirm what's permitted, and under what conditions, in every market in the study.
• Support the hybrid reality. Build a supply model that can serve both site-based and home-based patients simultaneously, because most studies need both.